Key result
hiPSC-CM exosomes improve cardiac function and reduce infarct size in a murine MI model.
Why the study?
Stem cell therapies for myocardial repair face retention, engraftment, and tumorigenic challenges, making the comparative efficacy and mechanisms of exosomes from hiPSCs versus hiPSC-CMs an important open question.
Does intramyocardial injection of hiPSC-CM-derived exosomes improve cardiac function and reduce infarct size in a murine myocardial infarction model?
Does intramyocardial injection of hiPSC-CM-derived exosomes improve cardiac function and reduce infarct size in a murine myocardial infarction model?
Exosomes derived from hiPSC-cardiomyocytes, enriched with miR-21-5p, offer a superior, cell-free therapeutic approach for improving cardiac function and reducing fibrosis post-myocardial infarction in a preclinical model.
Answers are grounded in this paper and cite their sources.
No change to MI care warranted; leaves open human translation of hiPSC-CM exosome therapy.
BACKGROUND Heart disease remains a leading cause of mortality worldwide, with existing treatments often failing to effectively restore damaged myocardium. Human-induced pluripotent stem cells (hiPSCs) and their derivatives offer promising therapeutic options; however, challenges such as low retention, engraftment issues, and tumorigenic risks hinder their clinical utility. Recent focus has shifted to exosomes (exos) - nanoscale vesicles that facilitate intercellular communication - as a safer and more versatile alternative. Understanding the specific mechanisms and comparative efficacy of exos from hiPSCs vs hiPSC-derived cardiomyocytes (hiPSC-CMs) is crucial for advancing cardiac repair therapies. AIM To evaluate and compare the therapeutic efficacy of exos secreted by hiPSCs and hiPSC-CMs in cardiac repair, and to elucidate the role of microRNA 21-5p (miR-21-5p) in the observed effects. METHODS We differentiated hiPSCs into CMs using small molecule methods and characterized the cells and their exos. RESULTS Our findings indicate that hiPSC-CMs and their exos enhanced cardiac function, reduced infarct size, and decreased myocardial fibrosis in a murine myocardial infarction model. Notably, hiPSC-CM exos outperformed hiPSC-CM cell therapy, showing improved ejection fraction and reduced apoptosis. We identified miR-21-5p, a microRNA in hiPSC-CM exos, as crucial for CM survival. Exos with miR-21-5p were absorbed by AC16 cells, suggesting a mechanism for their cytoprotective effects. CONCLUSION Overall, hiPSC-CM exos could serve as a potent therapeutic agent for myocardial repair, laying the groundwork for future research into exos as a treatment for ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2025) studied Myocardial infarction (n=50). hiPSC-CM-derived exosomes vs. PBS, iPSCs, hiPSC-CMs, and iPSC-exosomes was evaluated on Cardiac function (LVEF and LVFS) and infarct size (p=<0.05). Exosomes derived from human-induced pluripotent stem cell-derived cardiomyocytes significantly improved cardiac function, reduced infarct size, and decreased myocardial fibrosis in a murine myocardial infarction model.
Synapse has enriched 10 related papers. Consider them for comparative context: